New combo therapy aims to better control CMV in transplant patients
NCT ID NCT06853184
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 33 times
Summary
This study tests whether adding artesunate to standard antiviral drugs (ganciclovir or valganciclovir) can better reduce CMV virus levels in adults who have received a kidney, lung, heart, or liver transplant. About 90 participants will be randomly assigned to receive either the combination or standard treatment alone. The goal is to improve control of the infection, not to cure it, since transplant patients need lifelong immune-suppressing medications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CMV INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Princess Alexandra Hospital
RECRUITINGWoolloongabba, Australia
Contact Email: •••••@•••••
-
Westmead Hospital
RECRUITINGWestmead, Australia
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.